Oct 27, 2004 by Charly TraversCubist's Growing PainsWhen a great launch of a good drug is not enough.
Oct 26, 2004 by Charly TraversBiotech's 5-Baggers: Part 2Several hot drugs are generating smoking returns.
Oct 26, 2004 by Charly TraversSepracor's Tough Road to ProfitsWill insomnia drug Estorra take the company to the promised land?
Oct 18, 2004 by Charly TraversBiotech's 5-BaggersHow can yesterday's biotech winners lead you to today's top performers?
Oct 8, 2004 by Charly TraversGenentech's Wealth Transfer ProgramGenentech's stock is even more expensive than you think.
Oct 7, 2004 by Charly TraversAmgen's Next BlockbusterOsteoporosis drug could give the company its next big winner.
Oct 7, 2004 by Charly TraversSantarus Takes on Big PharmaCan this small drug company compete with the industry's giants?
Sep 30, 2004 by Charly TraversBiomira Drug's on the Fast TrackInvestors rally on the good news, but what does fast-track status really mean?
Sep 29, 2004 by Charly TraversNabi Stamps Out SmokingA nicotine vaccine looks to help smokers kick the habit.
Sep 10, 2004 by Charly TraversLooming Drug ShortagesThe push for drug re-importation into the U.S. will have consequences abroad.
Sep 9, 2004 by Charly TraversThe Case for Drug StocksThe reports of the drug industry's death are greatly exaggerated.
Sep 8, 2004 by Charly TraversWill a Clinical Trial Database Help Investors?How much will pharmaceutical companies divulge?
Sep 3, 2004 by Charly TraversMGI Pharma's Shopping SpreeThe company is filling out its drug pipeline with acquisitions.
Aug 31, 2004 by Charly TraversHidden Value With QLTThe market might overlook the drug maker's promising programs.
Aug 30, 2004 by Charly TraversIt's a Hard-Knock MarketWhen the market smacks you around, you wise up fast.
Aug 19, 2004 by Charly TraversMyriad's Making Hope PossibleThis small biotech provides screens that can help catch cancer.
Aug 19, 2004 by Charly Travers1 Pill for Sleep, Attention Ailments?Cephalon gets some good news about its drug PROVIGIL.
Aug 17, 2004 by Charly TraversSurviving Biotech's DownturnsCharly Travers offers advice on withstanding the volatility of the biotech sector.
Aug 13, 2004 by Charly TraversSmaller Market for Insomnia DrugsA market research report shows insurers might not cover some drugs for this condition.
